Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio Ltd.
https://european-biotechnology.com/wp-content/uploads/2024/07/Myricx_Bio3.png266522Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-07-08 09:31:082024-07-16 18:33:03Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd